<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hemoglobin</journal-id><journal-id journal-id-type="iso-abbrev">Hemoglobin</journal-id><journal-id journal-id-type="publisher-id">HEM</journal-id><journal-title-group><journal-title>Hemoglobin</journal-title></journal-title-group><issn pub-type="ppub">0363-0269</issn><issn pub-type="epub">1532-432X</issn><publisher><publisher-name>Informa Healthcare</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23614625</article-id><article-id pub-id-type="pmc">3667679</article-id><article-id pub-id-type="doi">10.3109/03630269.2013.775149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>Interaction of Hb Adana (<italic>HBA2</italic>: c.179G&#x0003e;A) with Deletional and Nondeletional <italic>&#x003b1;</italic>
<sup>+</sup>-Thalassemia Mutations: Diverse Hematological and Clinical Features</article-title><alt-title alt-title-type="right-running-head">Hb Adana Cases&#x02013;Hematological and Clinical Features</alt-title></title-group><contrib-group><contrib id="a1" contrib-type="author" corresp="no"><name><surname>Nainggolan</surname><given-names>Ita M.</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib id="a2" contrib-type="author" corresp="no"><name><surname>Harahap</surname><given-names>Alida</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib id="a3" contrib-type="author" corresp="no"><name><surname>Ambarwati</surname><given-names>Debby D.</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib id="a4" contrib-type="author" corresp="no"><name><surname>Liliani</surname><given-names>Rosalina V.</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>3</sup>
</xref></contrib><contrib id="a5" contrib-type="author" corresp="no"><name><surname>Megawati</surname><given-names>Dewi</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib id="a6" contrib-type="author" corresp="no"><name><surname>Swastika</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><contrib id="a7" contrib-type="author" corresp="yes"><name><surname>Setianingsih</surname><given-names>Iswari</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref></contrib><aff id="AF0001"><sup>1</sup><institution>Biomedical Sciences Doctoral Programme, Faculty of Medicine, University of Indonesia</institution>, <addr-line>Jakarta</addr-line>, <country>Indonesia</country></aff><aff id="AF0002"><sup>2</sup><institution>The Eijkman Institute for Molecular Biology</institution>, <addr-line>Jakarta</addr-line>, <country>Indonesia</country></aff><aff id="AF0003"><sup>3</sup><institution>Biochemistry Department, Faculty of Medicine, University of Sriwijaya</institution>, <addr-line>Palembang</addr-line>, <country>Indonesia</country></aff></contrib-group><author-notes><corresp id="C1">Address correspondence to Dr. Iswari Setianingsih, <institution>Eijkman Institute for Molecular Biology</institution>, <addr-line>Jalan Diponegoro 69, Jakarta Pusat, 10430</addr-line>, <country>Indonesia</country>; Tel.: <phone>+62-21-3917131</phone>; Fax: <fax>+62-21-3147982</fax>; E-mail: <email xlink:href="ning@eijkman.go.id">ning@eijkman.go.id</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>24</day><month>4</month><year>2013</year></pub-date><volume>37</volume><issue>3</issue><fpage>297</fpage><lpage>305</lpage><history><date date-type="received"><day>9</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; Informa Healthcare USA, Inc.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Informa Healthcare USA, Inc.</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by-nc/3.0/" license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="HEM-37-297.pdf"/><abstract><p>We describe 27 cases of mild-to-severe &#x003b1;-thalassemia (&#x003b1;-thal) syndrome caused by interaction of Hb Adana [&#x003b1;59(E8)Gly&#x02192;Asp, G<italic>G</italic>C&#x0003e;G<italic>A</italic>C (<italic>&#x003b1;</italic>2)] with deletional and nondeletional <italic>&#x003b1;</italic><sup>+</sup>-thal mutations in Indonesian patients. Hematological profiles and clinical manifestations of all patients were assessed by routine procedures. The genotypes were generated by a multiplex-polymerase chain reaction (m-PCR), PCR-RFLP (restriction fragment length polymorphism)-based method, and DNA sequencing. The <italic>&#x003b1;</italic>-thal patients who had Hb Adana in combination with the 3.7 kb deletion mostly have mild-to-moderate anemia. In contrast, patients who were compound heterozygotes for Hb Adana and nondeletional mutations, generally showed a more severe anemia and it mostly presented in childhood. Thus, accurate diagnosis of <italic>&#x003b1;</italic>-thal disorders is not only important for future management of these patients but also for providing proper genetic counseling to the family.</p></abstract><kwd-group><kwd>Hb Adana</kwd><kwd>Hematological features</kwd><kwd>&#x003b1;-Thalassemia (&#x003b1;-thal) mutations</kwd></kwd-group><counts><table-count count="4"/><ref-count count="9"/><page-count count="9"/></counts></article-meta></front><body><p>Hb Adana is a highly unstable variant hemoglobin (Hb) resulting from a mutation at codon 59 on the &#x003b1;1- or &#x003b1;2-globin gene (<italic>HBA1</italic>: c.179G&#x0003e;A or <italic>HBA2</italic>: c.179G&#x0003e;A) (<xref ref-type="bibr" rid="CIT0001 CIT0002">1,2</xref>). In Indonesia, we found Hb Adana on the &#x003b1;2-globin gene (<xref ref-type="bibr" rid="CIT0003 CIT0004">3,4</xref>). The most severe phenotype due to homozygous Hb Adana, manifesting as hydrops fetalis, has been previously reported (<xref ref-type="bibr" rid="CIT0003">3</xref>). Study of the frequency of Hb Adana trait in the Indonesian population has not yet been finished; however, our preliminary population study showed that this Hb variant was detected at a relatively low frequency (0.4%) in the Javanese population, although it is quite common (16.0%) in Indonesian patients (<xref ref-type="bibr" rid="CIT0004">4</xref>). It contributes to many kinds of &#x003b1;-thalassemia (&#x003b1;-thal) syndromes, especially in compound heterozygosity with the 3.7 kb deletion, which is the most common &#x003b1;<sup>+</sup>-thal deletion in Indonesia (<xref ref-type="bibr" rid="CIT0004">4</xref>). Interestingly, we also found the combination of Hb Adana with other nondeletional mutations such as Hb Constant Spring (Hb CS, <italic>HBA2</italic>: c.427T&#x0003e;C (<xref ref-type="bibr" rid="CIT0005">5</xref>), codon 22 (&#x003b1;2, <italic>HBA2</italic>: c.69C&#x0003e;T) (<xref ref-type="bibr" rid="CIT0006">6</xref>), a regulatory single nucleotide polymorphism (rSNP) 149709T&#x0003c;C (GenBank DQ431198) in a non genic region between the &#x003b6;- and &#x003b1;-globin genes (<xref ref-type="bibr" rid="CIT0007">7</xref>) that creates a new promoter causing &#x003b1;-thal [Online Mendelian Inheritance in Man (OMIM) 141800.0218] and IVS-II-142 (&#x003b1;2, <italic>HBA2</italic>: c.440+2G&#x0003e;A) (<xref ref-type="bibr" rid="CIT0008">8</xref>). In this study, we report the hematological and clinical features of patients having Hb Adana in combination with either deletional or nondeletional &#x003b1;<sup>+</sup>-thal mutations.</p><sec disp-level="2" id="S2001" sec-type="methods"><title>Selection of Patients and Features</title><p>Data used in this study was retrospectively evaluated including patients who were referred to the GenNeka Clinic (Yayasan GenNeka, Eijkman Institute for Molecular Biology, Jakarta, Indonesia) and were diagnosed with &#x003b1;-thal based on hematological parameters and molecular diagnosis. Clinical features including age of first presentation, clinical course and physical examination were recorded.</p></sec><sec disp-level="2" id="S2002"><title>Hematology Analysis and Molecular Studies</title><p>Hematological analysis consisted of complete blood counts (CBC), blood smear and Hb analysis. The CBCs were measured using Cell Dyne 1700 (Abbot Diagnostics, Abbott Park, IL, USA), erythrocyte morphology was assesed by blood smear examination under light microscope and Hb analysis was performed using high performance liquid chromatography (HPLC) on a VARIANT&#x02122; Hemoglobin Testing System (&#x003b2;-Thalassemia Short Program; Bio-Rad Laboratories, Hercules, CA, USA). Genomic DNA was isolated from leukocytes using modified Gentra Puregene Blood Kit (Qiagen Inc., Valencia, CA, USA) and used as a template for the polymerase chain reaction (PCR)-based mutation detection.</p></sec><sec disp-level="2" id="S2003"><title>Single <italic>&#x003b1;</italic> Gene Deletions [&#x02013;<italic>&#x003b1;</italic>
<sup>3.7</sup> (rightward) and &#x02013;<italic>&#x003b1;</italic>
<sup>4.2</sup> (leftward) types]</title><p>We performed multiplex-PCR (m-PCR) using primers as previously described (<xref ref-type="bibr" rid="CIT0004">4</xref>). Each 25 &#x003bc;L reaction mixture contained 5&#x000d7; KAPA2G GC Buffer (with MgCl<sub>2</sub>), 200 &#x003bc;M dNTPs (Invitrogen, Life Technologies Corp., Carlsbad, CA, USA), 0.2 &#x003bc;M of primers SA3P, XYHA and XY1, 0.1 &#x003bc;M of primers 3R1 and 2/3P (<xref ref-type="table" rid="T1">Table 1</xref>), 4.0% DMSO, 0.5 units of KAPA2G Robust HotStart DNA polymerase (5 U/&#x003bc;L) (KAPA Biosystems Inc., Woburn, MA, USA), and 100 ng of genomic DNA as template. The PCR was carried out on a Veriti&#x02122; 96-well thermal cycler (Applied Biosystems, Foster City, CA, USA) using the following conditions: initial denaturation at 95&#x000b0;C for 3 min.; 35 cycles at 95&#x000b0;C for 30 seconds, 62&#x000b0;C for 45 seconds, 72&#x000b0;C for 2 min.; then final extension at 72&#x000b0;C for 5 min. Product sizes of PCR were analyzed by electrophoresis on 1.0% agarose gel (LE Agarose, Roche Applied Science, Mannheim, Germany). The gel was photographed using Molecular Imager Gel Doc&#x02122; XR System (Bio-Rad Laboratories). Product sizes of PCR were 1940 bp for the normal band, 2220 bp for the &#x02013;3.7 kb mutant band, and 1673 bp for the &#x02013;4.2 kb mutant band. For nondeletional mutation detection, we first performed DNA sequencing and then developed and applied direct mutation detection [PCR-RFLP (restriction fragment length polymorphism)].</p><table-wrap id="T1" orientation="portrait" position="float"><label><bold>TABLE 1</bold>&#x02002;</label><caption><p>List of Primers Used to Detect Single &#x003b1;-Globin Gene Deletions (Ivy Ng, personal communication)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Primers</th><th align="center" rowspan="1" colspan="1">Sequences (GenBank: J00153.1) (5&#x02018;&#x0003e;3&#x02019;)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">2/3P</td><td rowspan="1" colspan="1">TGT TGG CAC ATT CCG GGA CAG</td></tr><tr><td rowspan="1" colspan="1">XY1</td><td rowspan="1" colspan="1">GCG CCG AGC CTG GCC AAA CCA TCA CTT TTC</td></tr><tr><td rowspan="1" colspan="1">3R1</td><td rowspan="1" colspan="1">TGC ATC CTC AAA GCA CTC TAG GGT CCA GCG T</td></tr><tr><td rowspan="1" colspan="1">SA3P</td><td rowspan="1" colspan="1">TAA GCT AGA GCA TTG GTG GTC ATG C</td></tr><tr><td rowspan="1" colspan="1">XYHA</td><td rowspan="1" colspan="1">GAA GTA GCT CCG ACC AGC TTA GCA A</td></tr></tbody></table></table-wrap><p>We carried out PCR-RFLP to detect the codon 59 mutation as previously described (<xref ref-type="bibr" rid="CIT0003">3</xref>). We developed a PCR-RFLP-based method to detect Hb CS, codon 22 and the IVS-II-142 mutations. For the Hb CS mutation detection, 25 &#x003bc;L reaction mixture contained 20 mM Tris-HCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 10 mM KCl, 2 mM MgSO<sub>4</sub>, 0.1% Triton X-100, pH 8.8, 200 &#x003bc;M dNTPs, 0.4 &#x003bc;M of each primer (<xref ref-type="table" rid="T2">Table 2</xref>), 0.625 units of Taq DNA polymerase (New England BioLabs Inc, Ipswich, MA, USA) and 100 ng of genomic DNA. Polymerase chain reactions were carried out on a 9700 thermal cycler (Applied Biosystems) using the following conditions: initial denaturation at 95&#x000b0;C for 5 min.; 35 cycles at 95&#x000b0;C for 30 seconds, 68&#x000b0;C for 30 seconds, 72&#x000b0;C for 1 min.; then a final extension at 72&#x000b0;C for 5 min.</p><table-wrap id="T2" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>List of Primers, Polymerase Chain Reaction Product Sizes, Restriction Enzymes and Restriction Fragment Length Polymorphism Product Sizes to Detect Nondeletional &#x003b1;-Thalassemia Mutations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Mutation</th><th align="center" rowspan="1" colspan="1">Primer Names and Sequences (GenBank: J00153.1) (5&#x02018;&#x0003e;3&#x02019;)</th><th align="center" rowspan="1" colspan="1">PCR Product Size (bp)</th><th align="center" rowspan="1" colspan="1">Restriction Enzymes</th><th align="center" colspan="3" rowspan="1">RFLP Product Size (bp)<hr/>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Normal</td><td rowspan="1" colspan="1">Heterozygote</td><td rowspan="1" colspan="1">Homozygote</td></tr><tr><td rowspan="1" colspan="1">Hb CS</td><td rowspan="1" colspan="1">E3a2: GCG GGT TGC GGG AGG T HbCS: GAA CGG CTA CCG AGG CTC CAG CT<italic>C</italic>
</td><td align="center" rowspan="1" colspan="1">222</td><td rowspan="1" colspan="1">
<italic>Taq</italic>
<sup>&#x003b1;</sup>-I</td><td align="center" rowspan="1" colspan="1">222</td><td align="center" rowspan="1" colspan="1">222; 200; 22</td><td align="center" rowspan="1" colspan="1">200; 22</td></tr><tr><td rowspan="1" colspan="1">Codon 22</td><td rowspan="1" colspan="1">&#x003b1;2&#x003b1;1PromF: GTG GAG GGT GGA GAC GTC &#x003b1;2R: GGA GGC CCA GCG GGC AGG AGG AAC</td><td align="center" rowspan="1" colspan="1">971</td><td rowspan="1" colspan="1">
<italic>Msl</italic>I, <italic>Alu</italic>I</td><td align="center" rowspan="1" colspan="1">559; 241; 130; 41</td><td align="center" rowspan="1" colspan="1">559; 495; 241; 130; 41; 64</td><td align="center" rowspan="1" colspan="1">495; 241; 130; 41; 64</td></tr><tr><td rowspan="1" colspan="1">rSNP<xref ref-type="fn" rid="T2-F1"><sup>a</sup></xref>149709T&#x0003e;C</td><td rowspan="1" colspan="1">0745F: GGG AGC ACC AGG ACA CAG ATG 149776R: CTT GCA CCA ACA GCT TTT CA</td><td align="center" rowspan="1" colspan="1">164</td><td rowspan="1" colspan="1">
<italic>Hpy</italic>188I</td><td align="center" rowspan="1" colspan="1">164</td><td align="center" rowspan="1" colspan="1">164; 85; 79</td><td align="center" rowspan="1" colspan="1">85; 79</td></tr><tr><td rowspan="1" colspan="1">IVS-II-142</td><td rowspan="1" colspan="1">E2a2: CCC GCC CGG ACC CAC A &#x003b1;2R: GGA GGC CCA GCG GGC AGG AGG AAC</td><td align="center" rowspan="1" colspan="1">599</td><td rowspan="1" colspan="1">
<italic>Alu</italic>I</td><td align="center" rowspan="1" colspan="1">258; 169; 130; 42</td><td align="center" rowspan="1" colspan="1">299; 258; 169; 130; 42</td><td align="center" rowspan="1" colspan="1">299; 258; 42</td></tr></tbody></table><table-wrap-foot><fn><p>Hb CS: Hb Constant Spring.</p></fn><fn id="T2-F1"><p>
<sup>a</sup> Primers and PCR-RFLP information provided by Dr. D.R. Higgs (MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK.)</p></fn></table-wrap-foot></table-wrap><p>For the detection of the codon 22 and IVS-II-142 mutations, each 25 &#x003bc;L reaction contained 5&#x000d7; Phusion GC Buffer containing 7.5 mM MgCl<sub>2</sub> as 1&#x000d7; final concentration, 200 &#x003bc;M dNTPs, 0.4 &#x003bc;M of each primer (<xref ref-type="table" rid="T2">Table 2</xref>), 6.0% DMSO, 0.5 Units of Phusion DNA Polymerase (New England BioLabs Inc.) and 100 ng of genomic DNA. The PCR conditions were as follows: initial denaturation at 95&#x000b0;C for 5 min.; 35 cycles at 95&#x000b0;C for 1 min., 62&#x000b0;C for 30 seconds, 72&#x000b0;C for 1 min.; then a final extension at 72&#x000b0;C for 5 min.</p><p>For the detection of the rSNP 149709T&#x0003c;C mutation, each 25 &#x003bc;L reaction contained 1&#x000d7; PCR buffer (Qiagen), 1&#x000d7; Q solution (Qiagen), 200 &#x003bc;M dNTPs, 0.2 &#x003bc;M of each primer (<xref ref-type="table" rid="T2">Table 2</xref>), 1 unit of HotStar Taq Polymerase (Qiagen) and 100 ng of genomic DNA. The PCR conditions were as follows: initial denaturation at 95&#x000b0;C for 15 min.; 35 cycles at 95&#x000b0;C for 1 min., 54&#x000b0;C for 1 min., 72&#x000b0;C for 1 min.; then a final extension at 72&#x000b0;C for 5 min.</p><p>Polymerase chain reactions to detect the nondeletional mutations were carried out on a 9700 thermal cycler (Applied Biosystems). Digestion, using appropriate restriction enzymes, was according to the manufacturer&#x02019;s instructions. All digested products were electrophoresed in 2.0% agarose. The gels were photograped using Gel Doc&#x02122; XR (Bio-Rad Laboratories). The PCR product sizes, restriction enzymes and RFLP product sizes are given in <xref ref-type="table" rid="T2">Table 2</xref>.</p><p>Twenty-seven cases were studied, 25 were of Indonesian ethnic background and two were Chinese. Eighteen cases (67.0%) were compound heterozygotes for Hb Adana and either the &#x02013;&#x003b1;<sup>3.7</sup> (17 cases) or &#x02013;&#x003b1;<sup>4.2</sup> (one case) mutations (<xref ref-type="table" rid="T3">Table 3</xref>), and nine cases (33.0%) were compound heterozygotes for Hb Adana and other nondeletional mutations (<xref ref-type="table" rid="T4">Table 4</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>TABLE 3</label><caption><p>Hematological and Clinical Data of Hb Adana Patients in Combination With One Gene Deletion at Diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Sex-Age</th><th align="center" rowspan="1" colspan="1">Hb (g/dL)</th><th align="center" rowspan="1" colspan="1">MCV (fL)</th><th align="center" rowspan="1" colspan="1">MCH (pg)</th><th align="center" rowspan="1" colspan="1">RDW (%)</th><th align="center" rowspan="1" colspan="1">Hb A<sub>2</sub> (%)</th><th align="center" rowspan="1" colspan="1">Hb F (%)</th><th align="center" rowspan="1" colspan="1">Hb X</th><th align="center" rowspan="1" colspan="1">Clinical Manifestation</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">M-0.25</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">71.0</td><td align="center" rowspan="1" colspan="1">19.0</td><td align="center" rowspan="1" colspan="1">20.0</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">22.0</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>; H</td><td rowspan="1" colspan="1">has been transfused since 3 months old<xref ref-type="fn" rid="T3-F2"><sup>b</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">M-0.25</td><td align="center" rowspan="1" colspan="1">9.5</td><td align="center" rowspan="1" colspan="1">65.2</td><td align="center" rowspan="1" colspan="1">21.4</td><td align="center" rowspan="1" colspan="1">19.6</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">8.5</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">one transfusion at 1 month old<xref ref-type="fn" rid="T3-F3"><sup>c</sup></xref>
</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">M-2</td><td align="center" rowspan="1" colspan="1">9.4</td><td align="center" rowspan="1" colspan="1">65.0</td><td align="center" rowspan="1" colspan="1">23.7</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">7.4</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1">splenomegaly; no transfusions</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">F-4</td><td align="center" rowspan="1" colspan="1">8.3</td><td align="center" rowspan="1" colspan="1">73.4</td><td align="center" rowspan="1" colspan="1">23.6</td><td align="center" rowspan="1" colspan="1">31.9</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">4.0</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1">has been transfused since at 3 years old</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">F-5</td><td align="center" rowspan="1" colspan="1">9.2</td><td align="center" rowspan="1" colspan="1">71.0</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">21.6</td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">1.4</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1">anemic since 4 years old</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">F-7</td><td align="center" rowspan="1" colspan="1">10.3</td><td align="center" rowspan="1" colspan="1">69.7</td><td align="center" rowspan="1" colspan="1">23.8</td><td align="center" rowspan="1" colspan="1">17.5</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">6.6</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1">transfused once at 6 years old (fever)</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">F-12</td><td align="center" rowspan="1" colspan="1">7.8</td><td align="center" rowspan="1" colspan="1">72.3</td><td align="center" rowspan="1" colspan="1">22.2</td><td align="center" rowspan="1" colspan="1">23.9</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">4.8</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1"><sup>a</sup></xref>
</td><td rowspan="1" colspan="1">not reported</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">M-14</td><td align="center" rowspan="1" colspan="1">10.2</td><td align="center" rowspan="1" colspan="1">65.9</td><td align="center" rowspan="1" colspan="1">22.5</td><td align="center" rowspan="1" colspan="1">17.9</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">1.3</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">not reported</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">F-17</td><td align="center" rowspan="1" colspan="1">9.5</td><td align="center" rowspan="1" colspan="1">70.7</td><td align="center" rowspan="1" colspan="1">23.1</td><td align="center" rowspan="1" colspan="1">21.1</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">high ferritin levels; no transfusions</td></tr><tr><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">M-22</td><td align="center" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">70.4</td><td align="center" rowspan="1" colspan="1">21.5</td><td align="center" rowspan="1" colspan="1">22.7</td><td align="center" rowspan="1" colspan="1">3.1</td><td align="center" rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">splenomegaly; transfused once at age 18</td></tr><tr><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">M-24</td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">83.0</td><td align="center" rowspan="1" colspan="1">25.0</td><td rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">1.8</td><td align="center" rowspan="1" colspan="1">1.9</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">no transfusions<xref ref-type="fn" rid="T3-F3">
<sup>c</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">F-26.5</td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">69.4</td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">21.9</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">transfused at age 25 (pregnancy) and again at age 25.5 old (infection); splenomegaly</td></tr><tr><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">F-31</td><td align="center" rowspan="1" colspan="1">7.5</td><td align="center" rowspan="1" colspan="1">71.7</td><td align="center" rowspan="1" colspan="1">24.4</td><td align="center" rowspan="1" colspan="1">42.1</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">transfused twice at age 29 (Hb 6.0 g/dL)</td></tr><tr><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">M-32</td><td align="center" rowspan="1" colspan="1">11.9</td><td align="center" rowspan="1" colspan="1">75.6</td><td align="center" rowspan="1" colspan="1">24.0</td><td align="center" rowspan="1" colspan="1">17.7</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">splenomegaly; high ferritin levels</td></tr><tr><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">M-34</td><td align="center" rowspan="1" colspan="1">9.5</td><td align="center" rowspan="1" colspan="1">83.8</td><td align="center" rowspan="1" colspan="1">25.5</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T3-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">no transfusions</td></tr><tr><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">F-34</td><td align="center" rowspan="1" colspan="1">9.0</td><td align="center" rowspan="1" colspan="1">77.2</td><td align="center" rowspan="1" colspan="1">23.0</td><td align="center" rowspan="1" colspan="1">23.3</td><td align="center" rowspan="1" colspan="1">2.4</td><td align="center" rowspan="1" colspan="1">1.5</td><td rowspan="1" colspan="1">N.D.</td><td rowspan="1" colspan="1">transfused during every pregnancy (P<sub>4</sub>A<sub>3</sub>), for a total of six times<xref ref-type="fn" rid="T3-F3">
<sup>c</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">F-42</td><td align="center" rowspan="1" colspan="1">8.4</td><td align="center" rowspan="1" colspan="1">72.6</td><td align="center" rowspan="1" colspan="1">23.4</td><td align="center" rowspan="1" colspan="1">20.2</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">1.8</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">transfused twice at age 33 (pregnancy); twice at 41&#x02013;42 years old (infection); hepatosplenomegaly</td></tr><tr><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">M-53</td><td align="center" rowspan="1" colspan="1">11.7</td><td align="center" rowspan="1" colspan="1">76.2</td><td align="center" rowspan="1" colspan="1">25.9</td><td align="center" rowspan="1" colspan="1">16.3</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">0.6</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">transfused once at 49 years old</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td char="&#x000b1;" rowspan="1" colspan="1">9.4&#x000b1;1.2</td><td char="&#x000b1;" rowspan="1" colspan="1">73.0&#x000b1;5.2</td><td char="&#x000b1;" rowspan="1" colspan="1">23.7&#x000b1;1.2</td><td char="&#x000b1;" rowspan="1" colspan="1">22.7&#x000b1;6.5</td><td char="&#x000b1;" rowspan="1" colspan="1">2.3&#x000b1;0.3</td><td char="&#x000b1;" rowspan="1" colspan="1">2.5&#x000b1;0.3</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>N.D.: not defined; RDW: red cell distribution width; patients 1 and 4 are transfusion-dependent; mean and standard deviations were calculated for patients more than 1-year-old.</p></fn><fn id="T3-F1"><p>
<sup>a</sup> Was seen on the HPLC system (VARIANT&#x02122;; Bio-Rad Laboratories) (10).</p></fn><fn id="T3-F2"><p>
<sup>b</sup> In transfused patients, hematology analysis was carried out after one (or several) blood transfusions had been received (Hb steady state) except in patient 1 where it was carried out before he had received his first blood transfusion.</p></fn><fn id="T3-F3"><p>
<sup>c</sup> The Hb analyses were not done on the HPLC system (VARIANT&#x02122;; Bio-Rad Laboratories).</p></fn><fn><p>
<italic>NB</italic>: All patients carry the Hb Adana mutation in combination with the &#x02013;&#x003b1;<sup>3.7</sup> kb type deletion except patient 16 who has the &#x02013;&#x003b1;<sup>4.2</sup> kb type instead.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>TABLE 4&#x02002;</label><caption><p>Hematological, Molecular and Clinical Data of Patients Carrying Hb Adana in Combination With Nondeletional &#x003b1;<sup>+</sup>-Thalassemia at Diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<italic>n</italic>
</th><th align="center" rowspan="1" colspan="1">Sex- Age</th><th align="center" rowspan="1" colspan="1">Hb (g/dL)</th><th align="center" rowspan="1" colspan="1">MCV (fL)</th><th align="center" rowspan="1" colspan="1">MCH (pg)</th><th align="center" rowspan="1" colspan="1">RDW (%)</th><th align="center" rowspan="1" colspan="1">Hb A<sub>2</sub> (%)</th><th align="center" rowspan="1" colspan="1">Hb F (%)</th><th align="center" rowspan="1" colspan="1">Hb X</th><th align="center" rowspan="1" colspan="1">Genotype</th><th align="center" rowspan="1" colspan="1">Notes</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">M-7 days</td><td align="center" rowspan="1" colspan="1">8.9</td><td align="center" rowspan="1" colspan="1">93.5</td><td align="center" rowspan="1" colspan="1">30.9</td><td align="center" rowspan="1" colspan="1">21.7</td><td align="center" rowspan="1" colspan="1">0.0</td><td align="center" rowspan="1" colspan="1">71.7</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>; H</td><td rowspan="1" colspan="1">codon 59/ Hb CS</td><td rowspan="1" colspan="1">not reported</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">M-4</td><td align="center" rowspan="1" colspan="1">9.8</td><td align="center" rowspan="1" colspan="1">80.2</td><td align="center" rowspan="1" colspan="1">26.5</td><td align="center" rowspan="1" colspan="1">16.6</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">1.7</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">codon 59/ Hb CS</td><td rowspan="1" colspan="1">transfused since &#x0003c;1 year old</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">F-14</td><td align="center" rowspan="1" colspan="1">9.0</td><td align="center" rowspan="1" colspan="1">76.4</td><td align="center" rowspan="1" colspan="1">23.9</td><td align="center" rowspan="1" colspan="1">29.1</td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">2.1</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">codon 59/ Hb CS</td><td rowspan="1" colspan="1">regularly transfused since 7 years old (3&#x02013;4/year)</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">F-28</td><td align="center" rowspan="1" colspan="1">8.1</td><td align="center" rowspan="1" colspan="1">85.5</td><td align="center" rowspan="1" colspan="1">23.5</td><td align="center" rowspan="1" colspan="1">24.1</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">1.6</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>; CS<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">codon 59/ Hb CS</td><td rowspan="1" colspan="1">first presented as a young adult</td></tr><tr><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">M-5</td><td align="center" rowspan="1" colspan="1">8.2</td><td align="center" rowspan="1" colspan="1">67.3</td><td align="center" rowspan="1" colspan="1">24.3</td><td align="center" rowspan="1" colspan="1">21.8</td><td align="center" rowspan="1" colspan="1">9.0</td><td align="center" rowspan="1" colspan="1">1.2</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">codon 59/ codon 22</td><td rowspan="1" colspan="1">irregularly transfused (+), high Hb A<sub>2</sub> is not due to coinheritance of Hb E<xref ref-type="fn" rid="T4-F2">
<sup>b</sup>
</xref>
</td></tr><tr><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">M-5</td><td align="center" rowspan="1" colspan="1">11.1</td><td align="center" rowspan="1" colspan="1">73.5</td><td align="center" rowspan="1" colspan="1">25.4</td><td align="center" rowspan="1" colspan="1">20.4</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">0.0</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">codon 59/ codon 22</td><td rowspan="1" colspan="1">regularly transfused since 1.5 years old (10&#x02013;12/year); has not been transfused since age 14</td></tr><tr><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">F-24</td><td align="center" rowspan="1" colspan="1">9.4</td><td align="center" rowspan="1" colspan="1">73.2</td><td align="center" rowspan="1" colspan="1">24.5</td><td align="center" rowspan="1" colspan="1">16.7</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">3.0</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">codon 59/ codon 22</td><td rowspan="1" colspan="1">only transfused while pregnant</td></tr><tr><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">F-12</td><td align="center" rowspan="1" colspan="1">8.7</td><td align="center" rowspan="1" colspan="1">81.1</td><td align="center" rowspan="1" colspan="1">27.1</td><td rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1">2.1</td><td align="center" rowspan="1" colspan="1">0.1</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">codon 59/ rSNP 149709T&#x0003e;C</td><td rowspan="1" colspan="1">regularly transfused since 2-months-old but not since age 9 after being splenectomized</td></tr><tr><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">F-3</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">71.7</td><td align="center" rowspan="1" colspan="1">23.6</td><td align="center" rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">2.4</td><td rowspan="1" colspan="1">Bart&#x02019;s<xref ref-type="fn" rid="T4-F1">
<sup>a</sup>
</xref>
</td><td rowspan="1" colspan="1">codon 59/ IVS-II-142</td><td rowspan="1" colspan="1">regularly transfused since 3.5 months old</td></tr></tbody></table><table-wrap-foot><fn><p>RDW: red cell distribution width; N.D.: not defined; codon 59: Hb Adana; CS: Hb Constant Spring.</p></fn><fn id="T4-F1"><p>
<sup>a</sup> Was seen on the HPLC system (VARIANT&#x02122;; Bio-Rad Laboratories) (10).</p></fn><fn id="T4-F2"><p>
<sup>b</sup> On HPLC, Hb E elutes at a similar time as Hb A<sub>2</sub>; the parents do not carry Hb E trait, maybe the blood donor carried Hb E trait.</p></fn></table-wrap-foot></table-wrap><p>Although the clinical manifestations in patients with Hb Adana in combination with single gene deletions were mostly mild, the onset varied widely from infant to late adult (1 month to 49 years old) with the steady state Hb levels ranging from 6.1 to 11.9 g/dL (9.4 &#x000b1; 1.2) (<xref ref-type="table" rid="T3">Table 3</xref>). Only two patients required regular blood transfusions, one of whom started at 3 months of age and one at 3 years old. Two patients first presented at quite a late age (42 and 49 years). Several patients had a slight increase in Hb F levels (patients 3, 4, 6 and 7 in <xref ref-type="table" rid="T3">Table 3</xref>) as previously described (<xref ref-type="bibr" rid="CIT0001 CIT0009">1,9</xref>). This phenomenon might be related with the increase of &#x003b3;-globin gene expression, which should be further elucidated.</p><p>The nondeletional mutations in <italic>trans</italic> to Hb Adana were Hb CS (four cases), codon 22 (three cases), rSNP 149709T&#x0003e;C mutation (one case) and IVS-II-142 (one case) (<xref ref-type="table" rid="T4">Table 4</xref>). The first presentation varies from 7 days to 28 years old, with the steady state Hb level ranging from 4.9 to 11.1 g/dL. Most patients (five out of nine) required regular blood transfusions, two patients required irregular blood transfusions, and only one patient did not require any blood transfusions. One patient, a compound heterozygote for Hb Adana and rSNP 149709T&#x0003e;C required regular blood transfusions since 2 months of age, but did not require them after a splenectomy at age 9 years. Two related patients (case 6 and 7) with the same genotype (Hb Adana and codon 22) showed very different clinical severity as thalassemia major and mild thalassemia intermedia. This situation was also found in patients with a compound heterozygosity for Hb Adana and Hb CS (<xref ref-type="table" rid="T4">Table 4</xref>).</p><p>Although Indonesian &#x003b1;-thal patients who had Hb Adana in combination with the 3.7 kb deletion generally have mild-to-moderate anemia, a few of them could manifest as severe anemia. This phenotype variation has been reported previously (<xref ref-type="bibr" rid="CIT0002 CIT0009">2,9</xref>). Patients who had Hb Adana in combination with nondeletional mutations mostly showed more severe symptoms than those who had it with single gene deletion as we can see from their blood transfusion status, and who presented at an earlier age. The clinical severities varied widely between patients, even for those with the same genotype. The diversity of the hematology profiles and clinical manifestations might be due to genetic or non genetic factors, further research is required to explain this phenotype variation. Moreover, traits of the Hb Adana (<xref ref-type="bibr" rid="CIT0003">3</xref>) and the other nondeletional &#x003b1;-thal mutations in this study exhibit a normal range of Hb level with mild reduction of red cell indices, such as codon 22 (MCV &#x0003e;70.0 fL, MCH &#x0003e;25.0 pg), rSNP 149709T&#x0003e;C (MCV &#x0003e;70.0 fL, MCH &#x0003e;22.0 pg) and IVS-II-142 (MCV &#x0003e;79.0 fL, MCH &#x0003e;26.0 pg). Therefore, routine DNA analysis, regardless of the hematology feature, is strongly suggested for diagnosis of &#x003b1;-thal in Indonesia, especially during antenatal screening.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors thank Professor Suthat Fucharoen, (Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Salaya Campus, Thailand) for valuable comments, suggestions and proofreading the manuscript; our thanks also to Dr. Trevor Jones for proofreading the manuscript. The authors also thank Dr. Pustika A Wahidiyat and Teny T Sari from the Department of Child Health, Cipto Mangunkusumo Hospital, Jakarta; Dr. Dasril Daud from the Department of Child Health, Medical Faculty, Hasanuddin University, Makassar, Intan Russianna from Gatot Subroto Hospital, Jakarta; Udjiani E. Pawitro from Tangerang Regional General Hospital, Tangerang, Banten, for referring the patients.</p><p>
<bold>Declaration of Interest:</bold> The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.</p></ack><ref-list><title>REFERENCES</title><ref id="CIT0001"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000c7;&#x000fc;r&#x000fc;k</surname><given-names>MA</given-names></name><name><surname>Dimovski</surname><given-names>AJ</given-names></name><name><surname>Baysal</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Hb Adana or &#x003b1;<sub>2</sub>59(E8)Gly&#x02192;Asp&#x003b2;<sub>2</sub>, a severely unstable &#x003b1;1-globin variant, observed in combination with the &#x02013;(&#x003b1;)20.5 kb &#x003b1;-thal-1 deletion in two Turkish patients</article-title><source>Am J Hematol</source><year>1993</year><volume>44</volume><issue>4</issue><fpage>270</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">8237999</pub-id></element-citation></ref><ref id="CIT0002"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traeger-Synodinos</surname><given-names>J</given-names></name><name><surname>Metaxotou-Mavrommati</surname><given-names>A</given-names></name><name><surname>Karagiorga</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Interaction of an &#x003b1;<sup>+</sup>-thalassemia deletion with either a highly unstable &#x003b1;-globin variant (&#x003b1;2, codon 59, GGC&#x02192;GAC) or a nondeletional &#x003b1;-thalassemia mutation (AATAAA&#x02192;AATAAG): comparison of phenotypes illustrating &#x0201c;dominant&#x0201d; &#x003b1;-thalassemia</article-title><source>Hemoglobin</source><year>1999</year><volume>23</volume><issue>4</issue><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">10569721</pub-id></element-citation></ref><ref id="CIT0003"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nainggolan</surname><given-names>IM</given-names></name><name><surname>Harahap</surname><given-names>A</given-names></name><name><surname>Setianingsih</surname><given-names>I</given-names></name></person-group><article-title>Hydrops fetalis associated with homozygosity for Hb Adana [&#x003b1;59(E8)Gly&#x02192;Asp (&#x003b1;2)]</article-title><source>Hemoglobin.</source><year>2010</year><volume>34</volume><issue>4</issue><fpage>394</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">20642338</pub-id></element-citation></ref><ref id="CIT0004"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Setianingsih</surname><given-names>I</given-names></name><name><surname>Harahap</surname><given-names>A</given-names></name><name><surname>Nainggolan</surname><given-names>IM</given-names></name></person-group><article-title>&#x003b1; Thalassaemia in Indonesia: phenotypes and molecular defects</article-title><source>Adv Exp Med Biol</source><year>2003</year><volume>531</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">12916780</pub-id></element-citation></ref><ref id="CIT0005"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>LI</given-names></name><name><surname>Baer</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>AN</given-names></name><name><surname>Welch</surname><given-names>QB</given-names></name></person-group><article-title>Hemoglobin Constant Spring (slow-moving hemoglobin X components) and Hemoglobin E in Malayan aborigines</article-title><source>Am J Hum Genet.</source><year>1973</year><volume>25</volume><issue>4</issue><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">4716657</pub-id></element-citation></ref><ref id="CIT0006"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harteveld</surname><given-names>CL</given-names></name><name><surname>Wijermans</surname><given-names>PW</given-names></name><name><surname>van Delft</surname><given-names>P</given-names></name><name><surname>Rasp</surname><given-names>E</given-names></name><name><surname>Haak</surname><given-names>HL</given-names></name><name><surname>Giordano</surname><given-names>PC</given-names></name></person-group><article-title>An &#x003b1;-thalassemia phenotype in a Dutch Hindustani, caused by a new point mutation that creates an alternative splice donor site in the first exon of the &#x003b1;2-globin gene</article-title><source>Hemoglobin.</source><year>2004</year><volume>28</volume><issue>3</issue><fpage>255</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">15481895</pub-id></element-citation></ref><ref id="CIT0007"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Gobbi</surname><given-names>M</given-names></name><name><surname>Viprakasit</surname><given-names>V</given-names></name><name><surname>Hughes</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter</article-title><source>Science.</source><year>2006</year><volume>312</volume><issue>5777</issue><fpage>1215</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">16728641</pub-id></element-citation></ref><ref id="CIT0008"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noguera</surname><given-names>NI</given-names></name><name><surname>Gonzalez</surname><given-names>FA</given-names></name><name><surname>Davoli</surname><given-names>RA</given-names></name><name><surname>Milani</surname><given-names>AC</given-names></name><name><surname>Villegas</surname><given-names>A</given-names></name></person-group><article-title>A novel splice acceptor site mutation of the &#x003b1;2-globin gene causing &#x003b1;-thalassemia</article-title><source>Hemoglobin.</source><year>2001</year><volume>25</volume><issue>3</issue><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="pmid">11570724</pub-id></element-citation></ref><ref id="CIT0009"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douna</surname><given-names>V</given-names></name><name><surname>Papassotiriou</surname><given-names>I</given-names></name><name><surname>Garoufi</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>A rare thalassemic syndrome caused by interaction of Hb Adana [&#x003b1;59(E8)Gly&#x02192;Asp] with an &#x003b1;<sup>+</sup>-thalassemia deletion: clinical aspects in two cases</article-title><source>Hemoglobin</source><year>2008</year><volume>32</volume><issue>4</issue><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">18654886</pub-id></element-citation></ref></ref-list></back></article>